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The Val985Met Insulin-Receptor Variant in the we have estimated the potential physiological impact
Danish Caucasian Population: Lack of Associations of the Val985Met receptor variant on the whole-body
with Non–Insulin-Dependent Diabetes Mellitus or insulin-sensitivity index and on both glucose-stimulated
Insulin Resistance serum insulin and C-peptide release in 380 study partici-
pants randomly recruited from a population of youngTo the Editor:
individuals 18–32 years of age, who, in 1979–80 andA recent study in a Dutch population sample has shown
again in 1984–85, as children, had participated ina strong association between a Val985Met missense mu-
blood-pressure surveys in a representative and speciﬁedtation in the insulin-receptor gene and the common form
part of Copenhagen city and who are characterized byof non–insulin-dependent diabetes mellitus (NIDDM)
an intravenous glucose-tolerance test in combination(5.6%, vs. 1.3% in the control population). The authors
with tolbutamide injection and who were analyzed inalso conclude that this Val985Met variant in the insulin
accordance with the Bergman minimal model (Clausenreceptor associates with hyperglycemia (’t Hart et al.
et al. 1996). In this study material we previously have1996).
reported changes in the whole-body insulin-sensitivityThe Val985Met missense mutation in exon 17 of the
index and glucose-stimulated insulin secretion in indi-insulin-receptor gene ﬁrst was found in sporadic form in
viduals carrying genetic variants in key proteins in thecohorts of NIDDM patients and later in control subjects
insulin-signaling cascade (Clausen et al. 1995; Hansen(O’Rahilly et al. 1991, 1992), although without conse-
et al. 1995).quences for the insulin-receptor phosphorylation, and,
Genotyping was performed by PCR ampliﬁcation ofinvestigated in vivo by overexpression in Chinese ham-
the entire exon 17 of the human insulin-receptor gene,ster-ovary cells, this Val985Met insulin-receptor variant
from 0.1 mg of genomic DNA, by use of 5 pmol eachhad normal phosphorylation in response to insulin (Flier
of intronic sense primer, 5-tgggtggaaggtggcgtcaga-3,et al. 1993). When studied in NIDDM pedigrees, this
and antisense primer, 5-tcaggaaagccagcccatgtc-3, yield-Val985Met insulin receptor variant did not segregate
ing a 353-bp DNA segment (Seino et al. 1990). BsaAIwith NIDDM, although carriers of the polymorphism
and RsaI restriction analyses of 10 ml of PCR producttended to have higher levels of postglucose load levels
were performed in separate 20-ml reactions. All the reac-of plasma glucose (Elbein et al. 1993).
tions were analyzed on a 2% agarose gel. Exon 17 ofIn an attempt to replicate the Dutch ﬁndings in the
the insulin-receptor gene contains two sites for BsaAIDanish Caucasian population, we have determined the
(ACGT) and only a single site for RsaI (GTAC). One ofdistribution of the three known polymorphisms in exon
the BsaAI sites is disrupted by the Val985Met (GTG/17 of the insulin-receptor gene in 254 unrelated Danish
ATG), as well as by the TAC984TAT polymorphism,Caucasian NIDDM patients recruited from the outpa-
and the other is disrupted by the CAC1058CAT poly-tient clinic at Steno Diabetes Center (Copenhagen) and
morphism, whereas the RsaI site is disrupted only byin 243 age-matched, unrelated, and glucose-tolerant
the TAC984TAT polymorphism. Therefore, dependingDanish Caucasian control subjects traced in the Danish
on the genotype, BsaAI restriction digestion of exon 17Central Population Register and living in the same area
of Copenhagen as the NIDDM patients. Furthermore, (353 bp) gives a combination of four major visible
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TAC984TAT polymorphism was .177 (95% CI .130–
.224), whereas it was .103 (95% CI .065–.141; P
õ .01) in the control population (obtained by x2 analy-
sis). This ﬁnding, however, we consider to be insigniﬁ-
cant, for two reasons. First, because of the comparison
of multiple polymorphisms, the normally accepted sig-
niﬁcance level of 5% will be 1.7% when adjusted for
comparison of the three different polymorphisms. Thus,
the association of TAC984TAT with NIDDM reaches
Figure 1 Diagram showing both the size of the PCR-ampliﬁed only borderline signiﬁcance. Second, there was no differ-
DNA segment of exon 17 in the insulin-receptor gene and the resulting ence in the reported prevalence of this polymorphism in
DNA fragments after digestion with the restriction endonucleases the Dutch NIDDM and control populations (’t Hart etBsaAI and RsaI.
al. 1996). We found no compound-heterozygous carri-
ers of both the Val985Met and the TAC984TAT poly-
morphisms.bands—353 bp (uncut), 310 bp, 265 bp, and 222 bp—
The third polymorphism (CAC1058CAT) had a car-but all bands exist together only in incompletely di-
rier frequency of .299 (95% CI .243–.355) in thegested samples. However, since BsaAI cannot distin-
NIDDM population and .314 (95% CI .256–.372) inguish the TAC984TAT from the Val985Met (GTG/
the control subjects. All three polymorphisms in exonATG) polymorphism, a RsaI restriction digestion also
17 of the insulin-receptor gene were in Hardy-Weinbergis needed, giving two major bands—353 bp and 265
equilibrium.bp (ﬁg. 1). Carriers of the TAC984TAT polymorphism
We could not see any impact of the Val985Met recep-or the Val985Met (GTG/ATG) polymorphism display
tor on the fasting, 1-h, and 2-h post–glucose loadeither a 353-bp or 310-bp band in the BsaAI digestion,
plasma glucose or serum insulin levels, neither in thebut, if they are wild type in the RsaI digestion (only one
population of NIDDM subjects nor in the control sub-band, at 265 bp), they are considered carriers (heterozy-
jects (data not shown). Serum insulin levels were deter-gous) of the Val985Met (GTG/ATG) polymorphism. All
mined by enzyme-linked immunosorbent assay with athe samples that had a 310-bp or a 353-bp fragment in
narrow speciﬁcity excluding des(31,32)-proinsulin andthe BsaAI restriction and a 353-bp fragment in the RsaI
intact proinsulin, when the DAKO insulin kit was ap-restriction were sequenced as described elsewhere (Han-
plied, with overnight incubation, as described elsewheresen et al. 1995), in order not to conceal any coupling
(Andersen et al. 1993).between the Val985Met (GTG/ATG) polymorphism
In the population-based sample of 380 young healthyand the TAC984TAT polymorphism. Samples with a
Danes, the carrier frequency of the Val985Met polymor-353-bp or 265-bp band, either together with (heterozy-
phism was .021 (95% CI .006–.036), and the carriergous) or without (homozygous) a 222-bp band, were
frequency of the TAC984TAT polymorphism was .128considered to be carriers of the CAC1058TAT polymor-
(95% CI .094–.162); the carrier frequency of the CAC1-phism. In the 254 NIDDM patients, the carrier fre-
058CAT polymorphism was .332 (95% CI .284–.380)quency of the Val985Met insulin receptor was .020 (.95
in this cohort (table 2). None of these frequencies dif-conﬁdence interval [95% CI] .003–.037) and .016 (95%
fered statistically from either that in the NIDDM cohortCI 0–0.037) in the 243 control subjects (table 1).
In the diabetic population, the carrier frequency of the or that in the control cohort. The eight young healthy
Table 1
Distribution of Insulin-Receptor Genotypes in the Danish Caucasian Population
NO. OF INDIVIDUALS
NIDDM Patients Control Subjects
CODON Wild Type Heterozygous Homozygous Wild Type Heterozygous Homozygous
Val985Met (gtg/atg) 249 5 0 239 4 0
TAC984TAT* 209 43 2 218 25 0
CAC1058CAT 178 69 7 166 70 7
* P õ .01, for carrier frequency.
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Table 2
Distribution of Insulin-Receptor Genotypes in 380 Young Healthy Caucasians
NO. OF INDIVIDUALS WITH GENOTYPE
CODON Wild Type Heterozygous Homozygous TOTAL NO. OF CARRIERS
Val985Met (gtg/atg) 372 8 0 8
TAC984TAT 334 44 2 46
CAC1058CAT 256 113 11 124
carriers of the Val985Met receptor variant had a whole- Val985Met polymorphism on the plasma glucose val-
ues—and that this occurred for two reasons: ﬁrst, thebody insulin-sensitivity index (Si) comparable to that of
the noncarriers, and no difference was seen in fasting authors used ‘‘random’’ plasma values—that is, not
fasting plasma glucose values—and the glucose valuesvalues of plasma glucose, serum insulin, and serum C-
peptide or in ﬁrst-phase insulin and C-peptide secretion are not adjusted for serum insulin levels (both insulin
deﬁciency and eating affect plasma glucose levels); sec-after intravenous glucose loads (table 3).
So, in the Danish Caucasian population, young ond, ’t Hart et al. (1996) analyze diabetic and nondia-
betic carriers of the Val985Met variant together, ratherhealthy carriers of the Val985Met receptor variant had
a normal whole-body insulin-sensitivity index and than analyzing diabetic noncarriers versus diabetic carri-
ers and nondiabetic carriers versus nondiabetic noncar-showed no signs of compensatory changes in insulin
secretion. Moreover, in contrast to the Dutch ﬁndings, riers. Since the diabetics represent 9/16 of all the carriers
but only 153/531 of the noncarriers, the hyperglycemiccarriers also had plasma glucose levels completely indis-
tinguishable from those of noncarriers, in all three diabetic carriers will dominate in the analysis and hence
tend to give a false impression of an association betweengroups studied. We suggest that ’t Hart et al. (1996)
may have overinterpreted the potential inﬂuence of the the Val985Met variant and hyperglycemia.
Both the prevalence (Ç2%) of the Val985Met poly-
morphism in the different groups studied in the Danish
Caucasian population and the lack of association withTable 3
NIDDM are in accordance with earlier reports
Mean and SD for Physiological Variables, according to Codon 985 (O’Rahilly et al. 1992; Elbein et al. 1993). Also, the fact
Insulin-Receptor Genotype, in 380 Young Healthy Caucasians that the nondiabetic carriers of the Val985Met polymor-
phism have intermediary metabolism that is indistin-MEAN (SD) FOR GENOTYPE
guishable from that of the noncarriers is consistent with
VARIABLE Val985Val Val985Met P previous studies of overexpression of this mutant recep-
tor, studies that showed normal autophosphorylation,
No. of males/no. of normal receptor internalization, and even an increased
females 182/190 4/4 downstream phosphorylation of insulin-receptor sub-Fasting plasma glucose
strate-1 (Flier et al. 1993; Strack et al. 1996). In conclu-(mmol/liter) 4.98 (.48) 5.04 (.38) .74
sion, in the Danish Caucasian population, theFasting serum insulin
(pmol/liter) 37 (22) 35 (15) .86 Val985Met polymorphism of the insulin receptor is not
Fasting serum C-peptide associated with an impaired insulin-sensitivity index or
(pmol/liter) 474 (161) 441 (89) .80 with NIDDM.
First-phase insulin (area
LARS HANSEN,1 TORBEN HANSEN,1 JESPER O.under curve 0–8 min)
(pmol/min/liter)a 2,247 (1,598) 2,131 (1,104) .95 CLAUSEN,2 SO/ REN M. ECHWALD,1 SO/ REN A.
First-phase C-peptide URHAMMER,1 SO/ REN K. RASMUSSEN,1
(area under curve 0–
AND OLUF PEDERSEN18 min) (pmol/min/ 1Steno Diabetes Center and Hagedorn Researchliter)a 7,076 (3,341) 7,404 (2,670) .60
Institute, and 2Center of Preventive Medicine,Insulin-sensitivity index
(1005 liter/pmol/min) 12.6 (2.3) 15.4 (9.4) .71 Glostrup University Hospital, Copenhagen
a Estimated as the incremental area under the curve during the ﬁrst Acknowledgments
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